This clinical trial is focused on studying a condition known as Acute-On-Chronic Liver Failure (ACLF), which occurs in people who already have liver cirrhosis and then experience a sudden worsening of their liver function. The study is particularly interested in patients with specific stages of this condition, referred to as ACLF-1b, ACLF-2, or ACLF-3a. These stages indicate varying levels of severity in the liver’s failure to function properly.

The treatment being tested in this study is called Human Serum Albumin, which is a protein derived from human blood. It is used in a solution form for infusion, meaning it is administered directly into the bloodstream through a vein. The specific product used in this trial is known as Albutein 50 g/l solution for infusion. The study aims to evaluate the effect of combining this treatment with standard medical care to see if it improves the 90-day survival rate of patients with ACLF.

Participants in the study will receive either the standard medical treatment alone or the standard treatment plus the Human Serum Albumin solution. The study will monitor the participants over a period to assess their overall survival and other health outcomes. The goal is to determine if the addition of the albumin solution can help improve the chances of survival for patients with this serious liver condition.